Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024

PRECIGEN, INC.

FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).
Cash and investments $62.9M; SG&A down 16% to support cost containment.
Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.
PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.
Recorded $10.4M goodwill impairment charge for Exemplar subsidiary.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2024, reporting its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-24-004017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.